| # | Drug | Count |
|---|---|---|
| 0 | MYCOPHENOLATE MOFETIL | 7 |
| 1 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 7 |
| 2 | TACROLIMUS | 7 |
| 3 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 7 |
| 4 | TACROLIMUS OINTMENT 0.1% | 7 |
| 5 | GANCICLOVIR SODIUM | 6 |
| 6 | VALGANCICLOVIR | 6 |
| 7 | VALGANCICLOVIR HYDROCHLORIDE | 6 |
| 8 | VALGANCICLOVIR HYDROCHLORIDE POWDER, | 6 |
| 9 | GANCICLOVIR | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN | 1 | 0.0021 |
| 1 | EQUINE THYMOCYTE IMMUNE GLOBULIN | 2 | 0.0019 |
| 2 | LIDOCAINE AND PRILOCAINE | 2 | 0.0014 |
| 3 | ALBENDAZOLE | 2 | 0.0011 |
| 4 | PENTAMIDINE ISETHIONATE | 1 | 0.0008 |
| 5 | GANCICLOVIR SODIUM | 6 | 0.0006 |
| 6 | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | 1 | 0.0005 |
| 7 | CALCIUM FOLINATE | 2 | 0.0004 |
| 8 | VALGANCICLOVIR | 6 | 0.0003 |
| 9 | SIROLIMUS | 4 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Anthelmintic [EPC] | 2 | 0.0007 |
| 1 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 7 | 0.0003 |
| 2 | Antimalarial [EPC] | 2 | 0.0002 |
| 3 | Antiprotozoal [EPC] | 2 | 0.0002 |
| 4 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 1 | 0.0001 |
| 5 | Nucleoside Analog Antiviral [EPC] | 5 | 0.0001 |
| 6 | CD52-directed Cytolytic Antibody [EPC] | 1 | 0.0001 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 1 | 0.0000 |
| 8 | Dihydrofolate Reductase Inhibitor Antibacterial [EPC] | 3 | 0.0000 |
| 9 | Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 3 | 0.0000 |